Copper-chelating drugs inhibits the expression of PD-L1 by downregulating phosphorylated STAT3, EGFR, AKT and GSK3β and mediates the ubiquitination and degradation of PD-L1 in cancer cells [179]. This evidence concerns the gene AKT1 and cancer.